CPC C07K 14/55 (2013.01) [A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 14/52 (2013.01); C07K 14/545 (2013.01); C07K 14/5418 (2013.01); C07K 14/5443 (2013.01); C07K 14/70596 (2013.01); C07K 16/2851 (2013.01); A61K 38/00 (2013.01)] | 5 Claims |
1. A method of expanding cytotoxic lymphocytes ex vivo, comprising culturing a population of lymphocytes in the presence of a chimeric peptide,
wherein the chimeric peptide comprises an orthopoxvirus major histocompatibility complex class 1-like protein (OMCP) peptide linked to an interleukin-2 (IL-2) mutant peptide comprising the amino acid sequence of SEQ ID NO: 5 comprising at least one mutation, wherein the at least one mutation is R38A, F42K, or C125S relative to SEQ ID NO: 5 wherein the OMCP peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 13, and SEQ ID NO: 14, and
wherein the population of lymphocytes comprises cytotoxic lymphocytes.
|